In the first one, Winner and colleagues found a statistical trend for better outcomes in a trial conducted in 51 study subjects (26 pharmacogenetic-guided versus 25 unguided) with baseline HDRS-17 scores ≥14 [ 18 ].
← all excerpts
Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial.
1
—
—